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ABSTRACT 
Background: Esophageal adenocarcinoma is a male dominant disease, but the role of 
androgens is unclear.   
 
Aims: To examine the expression and clinical correlates of the androgen receptor (AR) and 
the androgen-responsive gene FK506 binding protein 5 (FKBP5) in esophageal 
adenocarcinoma. 
 
Methods: Expression of AR and FKBP5 was determined by immunohistochemistry. The 
effect of the AR ligand 5α-dihydrotestosterone (DHT) on the expression of a panel of 
androgen-responsive genes was measured in AR-positive and AR-negative esophageal 
adenocarcinoma cell lines. Correlations in expression between androgen-responsive genes 
were analysed in an independent cohort of esophageal adenocarcinoma tissues. 
 
Results: There was AR staining in 75 of 77 cases (97%), and FKBP5 staining in 49 (64%), 
all of which had nuclear AR. Nuclear AR with FKBP5 expression was associated with 
decreased median survival (451 versus 2800 days), and was an independent prognostic 
indicator (HR 2.894, 95% CI 1.396 to 6.002, p = 0.0043) in multivariable Cox proportional 
hazards models. DHT induced a significant increase in expression of the androgen-responsive 
genes FKBP5, HMOX1, FBXO32, VEGFA, WNT5A and KLK3 only in AR-positive cells in 
vitro. Significant correlations in expression were observed between these androgen-
responsive genes in an independent cohort of esophageal adenocarcinoma tissues. 
 
Conclusion: Nuclear AR and expression of FKBP5 is associated with decreased survival in 
esophageal adenocarcinoma. 
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BACKGROUND 
Esophageal adenocarcinoma (EAC) is a dismal disease with a relative five year survival rate 
of 14% [1]. Its incidence has increased more rapidly than any other cancer over the last four 
decades in the West, but most markedly in males [2-4]. The major risk factors are gastro-
esophageal reflux disease and obesity, leading to the only described precursor lesion for the 
cancer, Barrett’s esophagus (BE). The reported ratio of males to females ranges from 7 - 10 
to 1 [4]. This ratio is highest in younger patients and lower in older patients [4], which is in 
part accounted for by an approximately 20 year delay in onset in females for BE [5] and EAC 
[6].  
 
The high ratio of males with this cancer, and the change in the ratio with age, suggests a role 
for the sex steroid hormones: their concentrations differ between males and females, and 
change over the lifespan. Serum estrogen and progesterone levels cycle about a relatively 
high mean in the adult female, and drop abruptly at menopause. Serum androgen levels are 
high in young adult males, and decline progressively throughout adulthood. However, 
evidence that these hormones play a role in EAC is limited. The male dominance could be, at 
least partly, explained by a protective effect of estrogens in females which is lost after 
menopause. Estrogen receptors have been reported in esophageal tissue [7, 8], and there are 
reports which suggest that estrogen is inhibitory to EAC cell lines [9].   
 
Alternatively, androgens could be involved in the biology of this cancer. There have been 
relatively few studies of androgens or androgen receptor (AR) signalling in EAC. Serum 
androgens have been reported to be elevated in both BE [10] and EAC [11]. Three previous 
studies investigated AR protein expression in EAC, but they examined relatively small 
patient cohorts, produced conflicting results, did not examine if AR was functional, and 
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reported no associations with survival [8, 11, 12]. Two epidemiological reports support a role 
for androgens. Prostate cancer patients given anti-androgen therapy had a statistically 
significant 30% risk reduction for EAC [13], and gastro-esophageal cancer was positively 
associated with a family history of prostate cancer [14].  
 
The androgen signalling cascade is activated by androgens, particularly testosterone and its 
metabolite 5α-dihydrotestosterone (DHT), which bind to the AR in the cytoplasm. The 
activated AR translocates to the nucleus and binds to androgen response elements in the 
genome. This binding may then result in the up- or down-regulation of transcription of 
androgen-responsive genes, such as FK506 binding protein 5 (FKBP5) [15-17], heme 
oxygenase 1 (HMOX1) [18], F-box protein 32 (FBXO32) [19], wingless-type MMTV 
integration site family, member 5A (WNT5A) [20], vascular endothelial growth factor A 
(VEGFA) [21] and kallikrein-related peptidase 3 (KLK3) [22]. The actual genes whose 
expression is altered is influenced by the interaction of AR and various co-regulators and is 
tissue and context dependent. FKBP5 expression is often used as an indicator of functional 
AR signaling, as in prostate cancer studies where it reflects better than any other AR target 
gene androgen levels after either short-term or long-term androgen deprivation therapy [23].  
 
Given the conflicting data on AR expression in EAC, and the lack of information as to 
whether, when present, it is functional, the specific aim of this study was to investigate AR 
expression and signalling in EAC. Associations between expression of AR and FKBP5 and 
clinicopathological parameters, including overall survival, were examined using 
multivariable Cox proportional hazards models to adjust for confounding parameters. The 
effect of DHT on the expression of androgen-responsive genes was assessed in AR-negative 
and AR-positive esophageal cancer cell lines. Correlations between the expression levels of 
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putative androgen-responsive genes were assessed using tissues from an independent cohort 
of patients with BE and EAC. 
 
 
MATERIALS AND METHODS 
Tissue microarrays and immunohistochemistry 
Specificity of all antibodies was confirmed by Western immunoblot, which included both 
positive and negative controls. Each antibody labeled a single band at the expected molecular 
weight. Antibodies then were optimized with control tissue blocks before application to the 
tissue microarrays. A tissue microarray composed of one or more representative cores from 
77 cases of EAC was constructed as previously described [24]. None of the patients had been 
given preoperative chemotherapy or radiotherapy. Sequential 4 m sections were mounted on 
polylysine-coated slides, dewaxed and rehydrated. Antigen retrieval was performed by 
heating the sections for 5 min in 10 mmol/L citrate buffer (pH 6) in a microwave pressure 
cooker. After cooling to room temperature, sections were immunostained using an 
Autostainer Plus (Dako, Glostrup, Denmark). Sections were incubated for 60 min with either 
1:50 rabbit anti-human AR (clone N-20, raised against the first 20 amino acids of the N-
terminus of AR) polyclonal IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or 
1:400 rabbit anti-human FKBP5 (FKBP51, clone H-100) polyclonal IgG (Santa Cruz 
Biotechnology Inc.). Slides were then incubated with MACH 4 Universal Horseradish 
Peroxidase-Polymer (Biocare Medical, Concord, CA, USA). Liquid 3,3-diaminobenzidine 
(Dako) was used as the chromogen, and sections were counterstained with Meyer’s 
haematoxylin. The staining was scored by an experienced gastrointestinal pathologist (ARR) 
and ES. Expression of AR was scored separately in the cytoplasm and the nucleus as positive 
(present in ≥ 5% of the tumor epithelial cells) or negative. Expression of FKBP5 was scored 
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as positive (present in ≥ 5% tumor epithelial cells) or negative. 
 
Cell lines 
The EAC cell lines OE33, OE19 and JH-EsoAd1 were maintained in RPMI-1640, and FLO-1 
in DMEM, supplemented with 10% foetal bovine serum, 4 mmol/L L-glutamine, 200 U/ml 
penicillin and 200 g/ml streptomycin. The esophageal squamous cell line TE7 was similarly 
maintained in RPMI-1640 plus supplements. All cells were incubated at 37oC with 5% CO2 
in air.  
 
Stable transduction of cell lines with androgen receptor 
The AR gene was amplified from the expression vector pCMV-AR3.1 using Gateway 
cloning compatible primers (Supplementary Table S1) and transferred into pLV411 plasmid 
using the Gateway cloning system, as previously described [25]. Stably transduced cells were 
selected using two rounds of fluorescence activated cell sorting for green fluorescent protein. 
The mock transduced OE33 and AR expressing cell line (OE33-AR) were maintained in 
phenol red free media supplemented with 10% dextran-coated charcoal-stripped foetal bovine 
serum, 4 mmol/L L-glutamine, 200 U/ml penicillin and 200 g/ml streptomycin (stripped 
medium).   
 
In vitro transactivation assay 
Cells were seeded at 15,000 cells per well in 96-well plates in stripped medium and incubated 
for 24 h. Cells were transiently transfected with either 50 ng of the synthetic minimal 
androgen-responsive luciferase probasin-driven promoter tk81-PB3 (PB3-luc) or 50 ng of 
PB3-luc and 2.5 ng of the androgen receptor expression vector pCMV-AR3.1 (AR) and 
incubated for 4 h, as previously described [26]. Cells were treated with either vehicle (V; 
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0.1% ethanol), 10 nmol/L DHT, 10 mmol/L of the anti-androgen bicalutamide (B), or 10 
nmol/L DHT and 10 mmol/L B (DHT + B) in stripped medium and incubated for 16 to 20 h. 
Cells were lysed and luciferase activity was measured using a FLUOstar Optima (BMG 
Labtech, Ortenberg, Germany). Whole-cell lysates from six replicate wells were pooled and 
analysed for protein expression by Western immunoblot. 
 
Western immunoblot analysis 
Cells were seeded at 2 x 105 cells per well in 6-well plates in stripped medium and incubated 
for 72 h. Cells were treated with either V, or 10 nmol/L DHT for 16 h. Whole-cell lysates 
were prepared and 15 g of protein was resolved by denaturing electrophoresis on 4-15% 
Mini-Protean TGX precast polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA), 
transferred to Hybond-C membrane (Amersham Biosciences, Castle Hill, NSW, Australia), 
and immnostained using 1:10,000 rabbit anti-human AR (N-20) polyclonal IgG, 1:4000 
rabbit anti-human FKBP5 (H-100) polyclonal IgG, and 1:5000 mouse anti-human -actin 
(clone AC-15) polyclonal IgG1 (Sigma-Aldrich, St Louis, MO). Immunoreactivity was 
detected using the appropriate horseradish peroxidase-conjugated IgG and visualized using 
enhanced chemiluminescence (Amersham). 
 
Measurement of gene expression by quantitative real-time reverse-transcription PCR 
Cells were seeded in stripped medium at 5 x 105 cells per well in 6-well plates, and incubated 
for 24 h. Cells were treated with either V or 10 nmol/L DHT in stripped medium and 
incubated for 4, 8 or 24 h. Total RNA was isolated using the RNeasy Mini Kit with on-
column DNase I digestion (Qiagen, Hilden, Germany). Total RNA (1 g) was reverse 
transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories) in a final volume of 
20 L. Gene expression was determined using iQ SYBR Green Supermix (Bio-Rad 
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Laboratories) in a final volume of 10 L, containing 0.1 L of cDNA and a final 
concentration of 0.2 mol/L of each forward and reverse primer (Supplementary Table S1). 
Triplicate reactions were performed using a CFX (Bio-Rad Laboratories) at 95oC for 3 min, 
then 40 cycles of 95oC for 15 s, 60oC for 15 s and 72oC for 30 s, followed by a final extension 
of 72oC for 1 min. The products were melted to confirm specificity. Normalized fold 
expression (∆∆Cq) was calculated using -actin (ATCB) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as reference genes using the CFX software. 
 
Statistical analysis 
The statistical software used was SAS 9.3 (SAS Institute Inc., Cary, NC, USA) and Prism 
6.0d for Macintosh (GraphPad Software, San Diego CA, USA; www.graphpad.com). Hazard 
ratios (HR), 95% confidence intervals (CI) and p values were calculated from univariate and 
multivariable Cox proportional hazards models. The proportional hazards assumption was 
found to be upheld for each univariate and multivariable regression. Initially each confounder 
that had a significant HR in univariate analysis (p < 0.1) was included in the multivariable 
model with the predictor being AR nuclear localization or FKBP5 expression or AR nuclear 
localization and FKBP5. However, there were too few observations to account for the ten 
covariates. Therefore, backwards stepwise elimination was performed. The confounder with 
the highest p value was eliminated, one at a time, until the final most parsimonious model 
had all confounders with p < 0.05 or p < 0.2 depending on the model. Normalized fold 
expression data were compared using unpaired t-test. Correlations between androgen-
responsive genes in esophageal tissues were determined using linear regression. All statistics 
were considered significant when the two-tailed p < 0.05. 
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RESULTS 
Expression of AR and FKBP5 in esophageal adenocarcinoma tissues 
The protein expression of AR and FKBP5 was investigated by immunohistochemistry in 
resection tissue from 77 cases of EAC (Fig. 1). Low to medium intensity staining of AR in 
tumor epithelial cells was observed in 75 of the 77 cases (97.4%). Nuclear localisation was 
observed in 70 cases (90.9%). There was nuclear only staining in seven cases (9.1%), 
cytoplasmic only in five (6.5%), and both nuclear and cytoplasmic in 63 (81.8%). 
 
Low to high intensity staining of FKBP5 in tumor epithelial cells was observed in 49 cases 
(63.6%). All of the FKBP5 positive cases also had nuclear localisation of AR. Of the 28 cases 
that did not express FKBP5, 21 had nuclear localisation of AR and seven did not. There was 
a significant association between FKBP5 expression and AR nuclear localisation (p = 
0.0005). These data suggest that in primary EAC epithelial cells, nuclear localisation of the 
AR is necessary but not sufficient for FKBP5 expression. 
 
Clinical significance of AR and FKBP5 in esophageal adenocarcinoma 
To determine the clinical significance of the expression of AR and FKBP5, we examined 
associations with clinicopathological data which was available for 76 of the cases. The 
median age of these patients at surgery was 64 years (range 36 to 81), the median follow-up 
time was 865 days (range 37 to 4,661), and the 5-year overall survival rate was 36.7%. 
 
Nuclear localisation of AR was significantly associated with the presence of BE 
(Supplementary Table S2; p = 0.0009). It was detected in all tissues from patients who had 
co-existing BE, but only 76.7% of tissues from patients without BE. There was no significant 
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difference in AR staining for patient age or gender. Patients with nuclear AR had a median 
overall survival of 671 days compared to 1,321 days for those without (Fig. 2A). 
 
Similarly, the expression of FKBP5 was more prevalent in patients with BE observable on 
endoscopy or in the resection specimen (Supplementary Table S2; p = 0.0495). Patients with 
FKBP5 expression had a median overall survival of 451 days compared to 1,338 days for 
those that were FKBP5-negative (Fig. 2B). For those patients who were FKBP5-negative but 
had nuclear AR (nuc AR+/FKBP5-), the median overall survival was 2,800 days (Fig. 2C). 
 
To investigate the difference between hazards of dying, univariate and multivariable Cox 
proportional hazards models were used. In univariate models neither AR nuclear localization 
nor FKBP5 expression were associated with a significant difference in risk of death 
(Supplementary Table S3). In multivariable models when adjusting for confounders, AR 
nuclear localization (HR 3.290, 95% CI 1.125 to 9.620, p = 0.0296) and FKBP5 expression 
(HR 3.043, 95% CI 1.417 to 6.531, p = 0.0043) were associated with a significant increase in 
risk of death (Supplementary Table S3). For the subset of patients who had AR nuclear 
localization, FKBP5 expression was not associated with a significant difference in risk of 
death in the univariate model (Table 1; HR 1.829, 95% CI 0.904 to 3.701, p = 0.0930). 
However, in the multivariable model, after adjusting for confounders, patients who had AR 
nuclear localization and FKBP5 expression had 2.9 times the hazard of dying (Table 1; HR 
2.894, 95% CI 1.396 to 6.002, p = 0.0043). 
 
AR and FKBP5 in esophageal cancer cell lines 
The expression of AR and FKBP5 protein was measured in esophageal cancer cell lines (Fig. 
3A). AR was not detected, nor induced by DHT, in OE33, OE19, JH-EsoAd1, FLO-1 or TE7. 
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FKBP5 expression was low in OE33, OE19, JH-EsoAd1 and TE7, higher in FLO-1, and not 
upregulated by DHT in any of these cell lines. 
 
Functional AR activity was not measured by transactivation assay in cell lines which were 
transiently transfected just with the synthetic minimal androgen responsive luciferase 
probasin-driven promoter tk81-PB3 (PB3-luc; Fig. 3B and 3C). No luciferase activity was 
induced over a broad concentration range of DHT (0.01 to 1000 nmol/L) in OE33 or at 10 
nmol/L in OE19, JH-EsoAd1 and FLO-1. However, transient co-transfection of both the AR 
expression vector pCMV-AR3.1 (AR) and the PB3-luc resulted in DHT induced luciferase 
expression (Fig. 3B and 3C). Expression of AR in these transiently co-transfected cells was 
confirmed by Western immunoblots (data not shown). Luciferase activity was dependent on 
the concentration of DHT, and was blocked by the anti-androgen bicalutamide. These results 
show that although functional AR was not expressed in the cell lines, they were competent 
for AR signalling. 
 
In order to examine the effect of AR signalling we stably transduced OE33 cells with AR, 
designating them OE33-AR. Expression of AR was confirmed by Western immunoblot (Fig. 
3A) and AR function was confirmed by transactivation assay (Fig. 3D). Treatment with DHT 
did not alter FKBP5 mRNA expression in the untransduced, AR-negative, OE33 cells (Fig. 
3E), but did induce a time-dependent increase in OE33-AR (Fig. 3F). Furthermore, the 
abundance of FKBP5 protein steady state levels in the OE33-AR cells was increased by DHT 
(Fig. 3A).   
 
Androgen-responsive genes in AR-positive cell line and esophageal tissues 
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To further explore the effect of functional AR in cell lines, we measured the effect of DHT 
on the expression of a panel of putative, clinically relevant androgen-responsive genes. 
Androgen-responsive genes have not been defined in EAC, so we measured expression of 
genes known to be androgen-responsive in other tissues and cell lines. DHT significantly 
increased the expression of HMOX1 (23-fold), FBXO32 (19-fold), WNT5A (4-fold), and 
VEGFA (3-fold), and induced the expression of KLK3 in the AR-positive OE33-AR, but not 
in the AR-negative OE33 (Fig. 4).   
 
To determine if this panel of androgen-responsive genes was also altered in an independent 
cohort of esophageal tissues, we looked for correlations between the genes in a publicly 
available transcriptional microarray dataset [27]. There were significant correlations between 
FKBP5 and each of the genes in the panel in EAC (Fig. 5). In contrast, there was no 
significant correlation in esophageal squamous mucosa (SQ) and the only correlations in BE 




We observed AR protein expression in tumor epithelial cells in 75 of 77 patients with EAC. 
There was nuclear localisation in 91% of these. The androgen-responsive gene FKBP5 was 
expressed in 64% of these tissues, but only in those which also had nuclear localisation of 
AR. Expression of either AR or FKBP5 was associated with decreased overall survival by 
multivariable analysis. We created an AR-positive EAC cell line, OE33-AR, by stably 
transducing the gene for AR into the AR-negative OE33. We found that DHT induced a time-
dependent increase in FKBP5 expression in the OE33-AR cells, but not the AR-negative 
OE33. Also, DHT increased expression of the androgen-responsive genes HMOX1, 
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FBXO32, WNT5A, VEGFA and KLK3. Correlations between the expression of these 
androgen-responsive genes were observed in an independent cohort of EAC tissues, 
consistent with functional AR being expressed in EAC.   
 
Ours is the largest cohort to date used to investigate AR protein expression in EAC. Three 
previous studies of AR expression in EAC have produced conflicting results. Focal staining 
was reported in one of 20 patients [8], in the tumor epithelial cells in five of 11 patients with 
no stromal expression [12], and in the stroma in 13 of 18 patients with no expression in the 
tumor epithelial cells [11]. In contrast, we observed a significantly higher incidence of AR 
expression and nuclear localisation in EAC tumor epithelial cells than the previous reports. 
There are several possible explanations for the discrepancy. There may be differences in the 
sensitivity of the staining methods or reporting thresholds, particularly as the abundance of 
AR in EAC is relatively low compared to, for example, prostate or breast cancer. Two of the 
studies used a different antibody to ours [11, 12], and although these two studies used the 
same antibody, one reported no staining of AR in the tumor epithelial cells, the other staining 
in 45% of cases. Variability of positivity and staining intensity between studies is not 
unusual. AR is expressed across a wide range of cancers, but for most cancers, just as with 
EAC, the published rates of expression vary widely, for reasons that are not clear [28].  
 
To determine if the AR signalling pathway was functional in EAC, we stained for the 
androgen-responsive gene FKBP5. Expression was only found in a subset of tumors which 
had nuclear localization of AR, suggesting that AR activation was required, but not 
sufficient, for FKBP5 expression. This was consistent with our cell line data, where DHT did 
not alter FKBP5 expression in the AR-negative EAC cell lines, but did in the AR-positive 
cell line, OE33-AR. 
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One explanation for our survival data is that the expression of FKBP5 is a marker of a 
functional AR signalling pathway which alters the expression of one or more genes which 
then reduce overall survival. In the nuclear AR-positive, FKBP5-negative cells, the AR 
pathway might not be functional, or is regulating different androgen-responsive genes from 
those in the FKBP5-positive tissues. This is consistent with recent studies which show that 
AR signalling is not a simple ligand-receptor-bind to specific DNA receptor elements model. 
Rather AR, like other steroid receptors, derives cell-specific transcription activity from 
interactions with various co-regulators and DNA-binding proteins that regulate receptor 
binding, and lineage-specific chromatin organization [29]. Alternatively, FKBP5 itself may 
influence survival, but in our tissues it is only expressed in cells with a functional AR 
signalling pathway, while in other contexts it may be expressed as a result of progestin or 
glucocorticoid signalling. 
 
Overexpression of FKBP5 has been reported in a range of solid tumors [30], including 
melanoma [31], glioma [32], colon [33], and prostate [34-37]. FKBP5 can inhibit apoptosis 
and promote cell proliferation in normal, premalignant and malignant tissues. In melanoma, 
expression correlated with tumor aggressiveness and was maximal in metastatic lesions [31] 
and in glioma expression correlated with stage and overall patient survival [32]. In contrast, 
down-regulation of FKBP5 has been reported in pancreatic cancer, and decreased expression 
resulted in hyperphosphorlyation of Akt and decreased cell death following genotoxic stress 
in cell lines [38]. These reports do not detail the AR status of the cancer tissues. Thus FKBP5 
may either be acting as a surrogate marker of a particular AR activated set of genes, or it may 
be the responsible gene itself. 
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None of the four common EAC cell lines we examined expressed AR. Lack of AR 
expression in cultured cell lines does not mean that the receptor was not present in the 
primary tissue from which the cell line was derived. Protein expression of steroid receptors, 
such as AR, present in cells of the primary tissue are frequently lost from the cells following 
culture, by mechanisms that are not clearly understood [39] [40]. However, these esophageal 
cell lines expressed the necessary co-regulators for AR signalling, as they exhibited AR 
transactivation activity following either transient transfection or stable transduction with the 
AR gene. We further showed that FKBP5, HMOX1, FBXO32, WNT5A, VEGFA and KLK3 
were androgen-responsive genes in the OE33-AR cell line following treatment with DHT. 
 
This is the largest study of AR expression in EAC and it shows that in most patients tumor 
epithelial cells express AR. This is the first study to show AR to be functional in the majority, 
but not all, cases of EAC, as defined by nuclear localisation and expression of the androgen 
responsive gene FKBP5. Significantly, it was sufficiently powered to show that AR and the 
androgen-responsive gene FKBP5 were independently associated with decreased overall 
survival. The correlation between nuclear localisation of AR and expression of FKBP5 in our 
cohort of EACs and the correlations between the expression of androgen-responsive genes in 
an independent cohort of patients, suggests that AR is functional in at least the majority of 
tumors. It further suggests that AR, FKBP5 or other androgen responsive-genes influence 
survival. These findings raise the possibility of novel therapeutic options for EAC, such as 
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